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Ameliorates Hypertensive Cardiomyopathy
Dao-Fu Dai, MD, PHD,* Tony Chen, BS,* Hazel Szeto, MD, PHD,‡ Madeline Nieves-Cintro´n, PHD,†
Vassily Kutyavin, BS,* Luis F. Santana, PHD,† Peter S. Rabinovitch, MD, PHD*
Seattle, Washington; and New York, New York
Objectives We investigated the effect of reducing mitochondrial oxidative stress by the mitochondrial-targeted antioxidant
peptide SS-31 in hypertensive cardiomyopathy.
Background Oxidative stress has been implicated in hypertensive cardiovascular diseases. Mitochondria and nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase have been proposed as primary sites of reactive oxygen spe-
cies (ROS) generation.
Methods The mitochondrial targeted antioxidant peptide SS-31 was used to determine the role of mitochondrial oxidative
stress in angiotensin II (Ang)-induced cardiomyopathy as well as in Gq overexpressing mice with heart failure.
Results Ang induces mitochondrial ROS in neonatal cardiomyocytes, which is prevented by SS-31, but not the nontar-
geted antioxidant N-acetyl cysteine (NAC). Continuous administration of Ang for 4 weeks in mice significantly
increased both systolic and diastolic blood pressure, and this was not affected by SS-31 treatment. Ang was as-
sociated with up-regulation of NADPH oxidase 4 (NOX4) expression and increased cardiac mitochondrial protein
oxidative damage, and induced the signaling for mitochondrial biogenesis. Reducing mitochondrial ROS by
SS-31 substantially attenuated Ang-induced NOX4 up-regulation, mitochondrial oxidative damage, up-regulation
of mitochondrial biogenesis, and phosphorylation of p38 mitogen-activated protein kinase and prevented apo-
ptosis, concomitant with amelioration of Ang-induced cardiac hypertrophy, diastolic dysfunction, and fibrosis,
despite the absence of blood pressure-lowering effect. The NAC did not show any beneficial effect. The SS-31
administration for 4 weeks also partially rescued the heart failure phenotype of Gq overexpressing mice.
Conclusions Mitochondrial targeted peptide SS-31 ameliorates cardiomyopathy resulting from prolonged Ang stimulation as
well as Gq overexpression, suggesting its potential clinical application for target organ protection in hyperten-
sive cardiovascular diseases. (J Am Coll Cardiol 2011;58:73–82) © 2011 by the American College of Cardiol-
ogy Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.044tHypertension is a major global health issue, accounting for
approximately one-half of the cases of stroke and ischemic
heart disease and approximately 13% of total death world-
wide (1). Systemic hypertension induces left ventricular
hypertrophy (LVH), fibrosis, and diastolic dysfunction and
increases the risk of coronary artery disease, which leads to
congestive heart failure (2). The renin-angiotensin aldoste-
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accepted December 14, 2010.rone system is the central regulator of hypertensive cardio-
vascular diseases. Angiotensin II (Ang) induces LVH,
cardiac fibrosis, and diastolic dysfunction. At the molecular
level, Ang binds to the angiotensin receptor-1 (ATR1), a
guanine nucleotide-binding protein type q alpha subunit
(Gq)-coupled receptor, then stimulates nicotinamide ad-
enine dinucleotide phosphate (NADPH) oxidases to pro-
duce reactive oxygen species (ROS) (3). Recent studies have
See page 83
reported that the nicotinamide adenine dinucleotide phos-
phate oxidase 4 (NOX4) isoform of NADPH oxidase is
present in mitochondria. The ROS generated by NADPH
oxidase was shown to stimulate mitochondrial ROS pro-
duction and induce mitochondrial dysfunction (4–7). Fur-
hermore, we previously demonstrated that mitochondrial
OS plays a key role in aging and lifespan regulation, as
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tension of lifespan in mice overex-
pressing catalase targeted to mito-
chondria (mCAT) (8). We further
showed that mCAT attenuated
age-dependent LVH and diastolic
dysfunction, concomitant with at-
tenuation of age-dependent in-
creases in cardiac mitochondrial
oxidative damage, without any ef-
fect on the increase of cardiac Ang
observed in aged mice (9). There-
fore, we hypothesized that Ang
might induce mitochondrial ROS
in cardiomyocytes and that scav-
enging mitochondrial ROS by a
mitochondrial-targeted antioxi-
dant peptide might be beneficial
in the setting of hypertensive
cardiomyopathy.
The Szeto-Schiller (SS)-31
peptide (D-Arg-2=,6=-dimethyl-
tyrosine-Lys-Phe-NH2) belongs
to a family of aromatic cationic
peptides that selectively target to
mitochondrial inner membrane
and can scavenge superoxide, hy-
drogen peroxide, peroxynitrite,
and hydroxyl radicals (10,11). The
SS-31 has been shown to reduce
mitochondrial ROS in epithelial,
endothelial, and neuronal cells ex-
posed to electron-transport-chain
nhibitors as well as pro-oxidants including t-butyl-
ydroperoxide and hypochlorous acid (12,13). The SS-31 also
nhibits apoptosis mediated by mitochondrial release of cyto-
hrome c elicited by mitochondrial permeability transition
11). In vivo administration of SS-31 has demonstrated efficacy
n several animal models associated with mitochondrial oxida-
ive stress, including reduction of ischemia-reperfusion injury
14), protection against neurodegeneration (15), and preven-
ion of insulin resistance induced by high-fat diet (16). In this
tudy, we demonstrated that Ang induced mitochondrial ROS
n cardiomyocytes and increased cardiac mitochondrial protein
xidative damage. Reduction of mitochondrial ROS by SS-31
meliorated Ang-induced cardiac hypertrophy, fibrosis, and
poptosis, concomitant with reduced activation of p38
itogen-activated protein kinase (MAPK). The SS-31 ad-
inistration also partially rescued the heart failure phenotype
f mice with Gq overexpression as a model of chronic
atecholamine/Ang stimulation (17).
ethods
etailed methods are provided in the Online Appendix.
Abbreviations
and Acronyms
Ang  angiotensin II
ATR1  angiotensin II
receptor-1
BP  blood pressure
HFpEF  heart failure with
preserved ejection fraction
LV  left ventricular
LVH  left ventricular
hypertrophy
MAPK  mitogen-activated
protein kinase
mCAT  catalase targeted
to mitochondria
NAC  N-acetyl cysteine
NADPH  nicotinamide
adenine dinucleotide
phosphate
NOX4  nicotinamide
adenine dinucleotide
phosphate oxidase 4
NRF  nuclear respiratory
factor
PGC-1  peroxisome
proliferator-activated
receptor gamma
co-activator
ROS  reactive oxygen
species
qPCR  quantitative
polymerase chain reactioneonatal mouse cardiomyocytes were stimulated with Ang1 mol/l), with or without simultaneous treatment of the
ollowing: SS-31 (1 nmol/l, kindly provided by Stealth
eptides, Inc., Newton Centre, Massachusetts), N-acetyl
ysteine (NAC) (0.5 mmol/l), 4-chlorodiazepam (25 mol/l),
diazoxide (200 mol/l), cyclosporine (0.5 mol/l), and/or
5-hydroxydecanoate (100 mol/l). Cardiomyocytes were then
loaded with MitoSOX (5 mol/l) and CM-DCFDA
5 mol/l) to measure mitochondrial superoxide and total
ellular ROS, respectively.
The FVBxC57BL/6J F1 hybrid mice (6 to 10/group,
pproximately 12 weeks of age) and wild-type littermates
ere treated with saline, Ang (1.1 mg/kg/day), Ang 
S-31 (3 mg/kg/day), Ang  NAC (approximately 500
g/kg/day in drinking water) (18), Gq (FVBxC57BL/6
2), or Gq SS-31 (3 mg/kg/day). Ang and SS-31 were
continuously administered for 4 weeks with subcutaneous
Alzet 1004 osmotic minipumps (Alzet, Cupertino, Califor-
nia). Echocardiography was performed at baseline and 4
weeks after pump. As a reference for SS-31 effects, we
included a genetic mouse model of Rosa-26 inducible-
mCAT (C57BL/6), in which mitochondrial catalase was
expressed 2 weeks before Ang treatment. Blood pressure
(BP) was measured in a separate group of mice by telemetry
with an intravascular catheter PA-C10 (DSI, St. Paul,
Minnesota). After 4 weeks of treatment, mouse ventricles
were harvested. Quantitative image analysis of trichrome
staining was performed to evaluate the severity of fibrosis.
Cardiac mitochondrial protein carbonyl content was ana-
lyzed with OxiSelect Protein Carbonyl ELISA Kit (Cell
Biolabs, San Diego, California). Quantitative polymerase
chain reaction (qPCR) was performed with Applied Bio-
systems 7900 thermocycler with Taqman Gene Expression
Assays on Demand (Applied Biosystems, Foster City,
California). Western blotting was used to analyze NOX4,
cleaved caspase-3, phosphorylated, and total p38 MAPK.
Statistical analysis. All data are presented as mean 
SEM. Comparisons between 2 groups are performed with
Student t tests. One-way analysis of variance was used to
compare differences among multiple groups, followed by
Tukey post hoc test for significance. All p values 0.05
were considered significant.
Results
Ang increased mitochondrial and total cellular ROS in
neonatal cardiomyocytes, which was alleviated by SS-31.
Flow cytometric analysis demonstrated that Ang in-
creased MitoSOX fluorescence (an indicator of mito-
chondrial superoxide) (Fig. 1A) and DCFDA fluores-
cence (an indicator of total cellular ROS) (Fig. 1B) in
neonatal cardiomyocytes by approximately 60% and 45%,
respectively (p  0.01 for both) (Fig. 1C). Treatment
with NAC, a nontargeted antioxidant drug, did not show
any significant effect on mitochondrial or total cellular
ROS after Ang. In contrast, SS-31 significantly reduced
Ang-induced MitoSOX and DCFDA fluorescence to
75JACC Vol. 58, No. 1, 2011 Dai et al.
June 28, 2011:73–82 Mitochondrial Antioxidant and CardiomyopathyFigure 1 Ang-Increased Mitochondrial and Total Cellular Oxidative Stress in
Neonatal Cardiomyocytes Is Prevented by SS-31 But Not NAC
Flow cytometry of neonatal cardiomyocytes stimulated with Angiotensin II (Ang) (1 mol/l) and loaded with MitoSOX (A) or CM-DCFDA (B). (C) Quantitative analysis (pre-
sented as mean  SEM of histogram medians, n  3 to 5) revealed a significant increase in MitoSOX and DCFDA fluorescence in Ang-treated cardiomyocytes (red),
compared with saline treatment (black). The nontargeted antioxidant N-acetyl cysteine (NAC) (0.5 mmol/l) (blue line) had no significant effect on Ang-induced mitochon-
drial reactive oxygen species (ROS) (A, C) and total cellular ROS (B, C). Simultaneous treatment with SS-31 (1 nmol/l) (green line) substantially reduced Ang-induced
mitochondrial ROS (A, C) and total cellular ROS (B, C). *p  0.01 versus saline; #p  0.01 versus Ang.Figure 2 No Effect of SS-31 on BP Increase After Pressor Dose of Ang
(A) Representative blood pressure (BP) tracings of mice at baseline and after angiotensin II (Ang) (1.1 mg/kg/day) administered with a subcutaneous pump. (B) Ang significantly
increased systolic and diastolic BP. Administration of SS-31 (3 mg/kg/day) did not show any significant effect on BP when added to Ang treatment (n  3).
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Mitochondrial Antioxidant and Cardiomyopathy June 28, 2011:73–82near control levels (Fig. 1). Ang-induced MitoSOX and
DCFDA fluorescence could also be attenuated by 4-Cl-
benzodiazepam, an inhibitor of the inner mitochondrial
anion channel, or cyclosporine A, an inhibitor of the
mitochondrial permeability transition pore or diazoxide,
an activator of the mitochondrial K-ATP channel
(Online Figs. 1A to 1D and 1G)—further supporting
mitochondrial mechanisms of ROS induction (see Dis-
cussion). In contrast, 5-hydroxydecanoate, an inhibitor of
the mitochondrial K-ATP channel, did not significantly
affect Ang-induced ROS (Online Figs. 1E and 1F).
SS-31 ameliorates Ang-induced cardiomyopathy despite
the absence of pressor effects. To recapitulate hyperten-
sive cardiomyopathy, we administered a pressor dose of Ang
(1.1 mg/kg/day) for 4 weeks via subcutaneous pumps.
Intravascular telemetry (Fig. 2) revealed Ang-induced sys-
tolic and diastolic BP increases of 25 to 28 mm Hg above
Figure 3 SS-31 Ameliorates Ang-Induced Cardiac Hypertrophy a
(A) Angiotensin II (Ang) for 4 weeks substantially increased left ventricular (LV) ma
ated this increase in LV mass index (left). This was to an extent similar to that ob
(right). (B) Fractional shortening (FS) was not significantly changed after 4 weeks
measured by tissue Doppler imaging of Ea/Aa was significantly reduced after Ang
tration of N-acetyl cysteine (NAC) for 4 weeks did not confer any significant protection
n  6 to 7.baseline (BP: 118.8 4.0/94.5 3.5 mm Hg at baseline vs.
146.0  5.6/119.3  4.0 mm Hg after Ang, p  0.001).
Simultaneous administration of SS-31 did not show any
effect on BP.
After 4 weeks of Ang, echocardiography revealed an
approximately 2-fold increase in left ventricular (LV) mass
index compared with baseline (Fig. 3A), no change in LV
end diastolic diameter (data not shown) or systolic function
as measured by fractional shortening (FS) (Fig. 3B), and an
approximately 35% decline in Ea/Aa, an indicator of dia-
stolic function (Fig. 3C). Simultaneous administration of
SS-31 significantly ameliorated Ang-induced cardiac hyper-
trophy and diastolic dysfunction, with a 33% reduction of
LV mass index (Ang: 6.32 0.39 vs. Ang SS-31: 4.21
0.17 mg/g, p  0.001) (Fig. 3A, left panel) and better
preservation of Ea/Aa (Ang: 0.723  0.15 vs. AngSS-31:
1.17  0.11, p  0.04) (Fig. 3C, left panel). These effects
iastolic Dysfunction
ex in control mice. Simultaneous administration of SS-31 significantly attenu-
d in mice with inducible overexpression of mitochondrial catalase (i-mCAT)
in the presence or absence of mitochondrial antioxidants. (C) Diastolic function
s significantly ameliorated by SS-31 or genetic overexpression of mCAT. Adminis-
g-induced hypertrophy and diastolic dysfunction (light blue bar on left panel, A to C),nd D
ss ind
serve
of Ang
but wa
for An
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dria (inducible mCAT), in which induction of mitochon-
drial catalase 2 weeks before Ang also conferred protection
against Ang-induced cardiac hypertrophy and diastolic dys-
function (Figs. 3A to 3D, right panels). To investigate
whether the protective effect is specific to a mitochondrial
targeted antioxidant, we administered the nontargeted an-
tioxidant NAC in drinking water for 4 weeks simultane-
ously with the Ang pump. This treatment has been shown
to ameliorate cardiomyopathy after acute aortic banding in
mice (18); however, it did not show any beneficial effect on
Ang-induced cardiomyopathy (Figs. 3A to 3C).
Ang increased heart weights by 45% above those of
saline-treated control subjects (Fig. 4A) (5.3  0.18 in
saline vs. 7.69  0.20 in Ang, p  0.001), and SS-31
protected heart weights (6.05  0.14 mg/mm, p  0.01 vs.
Ang alone), whereas oral NAC did not show any significant
protection of heart weights (7.13  0.7 in Ang NAC vs.
Figure 4 Ang-Induced Cardiac Hypertrophy and Fibrosis Were A
(A) Angiotensin II (Ang) significantly increased heart weight (normalized to tibia len
(B) Quantitative polymerase chain reaction (qPCR) showed a dramatic increase in
but not by NAC. (C) Representative histopathology showing that Ang-induced subs
SS-31 but not NAC. (D) Analysis of blue trichrome staining demonstrated a signifi
SS-31 but not NAC. (E) The qPCR showed up-regulation of pro-collagen1a2 messe
but not in NAC hearts; n  4 to 7.7.69  0.20 in Ang, p  0.47). The cardiac hypertrophyphenotype was confirmed by qPCR for atrial natriuretic
peptide, a fetal gene reactivated during hypertrophy. Ang
induced an approximately 15-fold increased atrial natri-
uretic peptide gene expression, which was almost completely
protected by SS-31, with no protection observed in the
NAC-treated hearts (Fig. 4B). Masson trichrome staining
demonstrated perivascular fibrosis and interstitial fibrosis
after Ang (Fig. 4C). Ang significantly increased ventricular
fibrosis, which was attenuated by SS-31 (Fig. 4D). This was
confirmed by qPCR of the procollagen 1a2 gene, the main
component of cardiac fibrosis. As shown in Figure 4E,
Ang-induced Coll1a2 gene expression was almost fully
attenuated by SS-31. Oral NAC showed a nonsignificant
reduction of ventricular fibrosis and Coll1a2 gene expression
(Figs. 4D and 4E).
Ang-induced mitochondrial protein oxidative damage
and signaling for mitochondrial biogenesis. Consistent
with studies of ROS in cardiomyocytes (Fig. 1), chronic
ated by SS-31 But Not Oral NAC
nd this was significantly attenuated by SS-31 but not by N-acetyl cysteine (NAC).
natriuretic peptide gene expression, which was significantly prevented by SS-31
perivascular fibrosis (PVF) and interstitial fibrosis (IF), which was protected by
crease in ventricular fibrosis after Ang, and this was substantially attenuated by
ibonucleic acid (mRNA) after Ang, which was significantly reduced in SS-31 heartsttenu
gth), a
atrial
tantial
cant in
nger radministration of Ang for 4 weeks significantly increased
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dicator of protein oxidative damage (p  0.03) (Fig. 5A).
his was significantly reduced by SS-31 (p  0.02)
Fig. 5A), whereas nontargeted NAC did not show any
ignificant reduction of mitochondrial protein oxidative
amage (1.27  0.1 in Ang  NAC vs. 1.44  0.1 in Ang,
 0.19) (Fig. 5A).
Peroxisome proliferator-activated receptor gamma co-
ctivator (PGC-1) is known as a master regulator of mito-
chondrial biogenesis, regulating nuclear respiratory factors
(NRFs) and mitochondrial transcription factor A, which tran-
scribe nuclear deoxyribonucleic acid and mitochondrial deoxy-
ribonucleic acid-encoded mitochondrial proteins, respectively
(19). Ang induced the expression of PGC-1 and its down-
stream target genes, including mitochondrial transcription
factor A, NRF-1, and NRF-2 (Fig. 5B). The SS-31 fully
prevented this up-regulation of PGC-1 and target genes (p
0.05 for all) (Fig. 5B), whereas NAC did not show significant
attenuation of any of these transcription factors.
SS-31 attenuates Ang-induced up-regulation of NOX4
and reduces activation of p38 MAPK and apoptosis.
Cardiac NOX4 protein expression was significantly in-
Figure 5
Mitochondrial Protein Carbonyl and Signaling for
Mitochondrial Biogenesis Increased After 4 Weeks
of Ang Treatment, Which Was Prevented by SS-31
(A) Ang significantly increased cardiac mitochondrial protein carbonyl content
and was significantly ameliorated by SS-31 but not by NAC. (B) The qPCR
revealed significant up-regulation of genes in mitochondrial biogenesis, all of
which were attenuated by SS-31. The NAC treatment did not significantly
change any genes in mitochondrial biogenesis signaling. *p  0.05 compared
with saline group, #p  0.05 compared with Ang-treated group, n  4 to 7.
NRF  nuclear respiratory factor; PGC-1  peroxisome proliferator-activated
receptor gamma co-activator; TFAM  transcription factor A; other abbrevia-
tions as in Figure 4.creased in Ang-treated and Gq overexpressing hearts (p 0.01) (Fig. 6A), consistent with a recent report by Ago et al.
(6). The SS-31 significantly reduced NOX4 up-regulation
in Ang-treated hearts (p  0.05) and trended toward
reduction of NOX4 up-regulation in Gq hearts (p 0.06)
(Fig. 6A), whereas NOX4 up-regulation was not attenuated
by NAC (p  0.19) (Online Fig. 2A).
Excessive mitochondrial ROS is well-known to induce
apoptosis. Activated (cleaved) caspase 3, a marker of apo-
ptosis, was increased in Ang-treated ventricular tissue (p 
0.006), and this was almost completely attenuated by SS-31
(p  0.004) (Fig. 6C). In contrast, NAC treatment did not
reduce Ang-induced cleaved caspase-3 (Online Fig. 2B).
Ang treatment increased phosphorylation of p38 MAPK,
and this was significantly attenuated by both SS-31 and
NAC (Fig. 6B, Online Fig 2C), suggesting that p38
phosphorylation depends on total ROS, regardless of the
location in mitochondria or cytosol.
SS-31 partially rescues Gq overexpression-induced
heart failure. To extend our observations to a model of
chronic catecholamine/Ang stimulation, we applied the
genetic mouse model of cardiac-specific overexpression of
Gq (a coupling protein to catecholamine and Ang recep-
tors), which causes heart failure in mice by 14 to 16 weeks
of age, despite the absence of increased BP (17). We
confirmed that Gq mice had impaired systolic function at
16 weeks old, as shown by a substantial decline in FS
(Fig. 7A), with LV chamber enlargement (Fig. 7B); dia-
stolic dysfunction, indicated by Ea/Aa 1 (Fig. 7C); and
worsening of the myocardial performance index (Fig. 7D).
SS-31 administered from 12 to 16 weeks of age significantly
reduced cardiac enlargement (p  0.001) (Fig. 7E), ame-
liorated systolic function (p  0.001 vs. untreated Gq)
Fig. 7A), and improved myocardial performance (p 0.04)
Fig. 7D). There were trends toward amelioration of LV
hamber enlargement (p  0.08) (Fig. 7B) and preservation
f Ea/Aa (p  0.06) (Fig. 7C) in SS-31–treated Gq mice.
here was a trend toward partial attenuation of increased
ung weights by SS-31 (p  0.09) (Fig. 7E). Ventricular
fibrosis increased by approximately 2-fold in Gq mice,
hich was not changed in SS-31–treated mice (Online
ig. 3A), and this was confirmed by pro-collagen 1a2 qPCR
Online Fig. 3B). Mitochondrial protein oxidative damage
as evident in Gq hearts (p 0.01) (Online Fig. 3C), and
S-31–treated mice displayed significant reduction of car-
iac mitochondrial protein carbonyls (p  0.05) (Online
ig. 3C). There was no evidence of increased cleaved-
aspase 3 in Gq mouse hearts (data not shown).
Discussion
We found that mitochondrial ROS plays an essential role in
hypertensive cardiomyopathies downstream of Ang and
protection from mitochondrial ROS by a mitochondrial-
targeted antioxidant confers resistance to cardiomyopathy,
whereas nontargeted antioxidant NAC did not. Our study
provides direct evidence that Ang induces mitochondrial
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(Fig. 1). We suggest that ROS amplified in mitochondria
subsequently activates downstream ROS-sensitive signaling
pathways implicated in pathological cardiac hypertrophy,
including p38 MAPK (Fig. 6C), apoptosis signal-regulating
kinase (20), other MAPKs (21), NF-B (22), and cal-
ineurin–nuclear factor of activated T-cells (23).
Exposure to Ang for 4 weeks increased cardiac mitochon-
rial protein oxidative damage and induced the signaling for
itochondrial biogenesis (Fig. 5), consistent with the pre-
ious report that hydrogen peroxide directly activates tran-
cription of PGC-1, the master regulator of mitochondrial
iogenesis (24). SS-31 significantly attenuated Ang-
nduced mitochondrial oxidative stress, reduced up-
egulation of mitochondrial biogenesis, and reduced ROS-
ediated p38 MAPK signaling (Fig. 8). Because inhibition
f p38 has been shown to improve cardiac remodeling and
nflammation and preserve cardiac function in heart failure
25,26), the attenuation of Ang-induced p38 phosphoryla-
ion by SS-31 might be one of the downstream mechanisms
Figure 6 SS-31 Reduces Ang-Induced Up-Regulation of NOX4, A
(A) NADPH oxidase-4 (NOX4) protein was significantly increased after 4 weeks of
SS-31. (B) Ang for 4 weeks substantially induced apoptosis, as shown by increas
Phosphorylation of p38 mitogen-activated protein kinase (MAPK) was significantly
Protein levels of p38 MAPK also increased after Ang, n  3 to 6. GAPDH  glycernderlying protection by SS-31. Furthermore, mitochon-rial ROS can lead to apoptosis, and our results confirm
hat SS-31 prevented caspase-3 activation (Fig. 6), concom-
tant with amelioration of Ang-induced cardiomyopathy
Figs. 3 and 4).
It has been proposed that Ang mediates its effects via
q. However, Gq transgenic overexpression involves a
ersistent lifelong stimulation of Gq, starting from devel-
opmental stage, and is likely a stronger stimulus than
obtained with Ang. Thus, transgenic overexpression of Gq
displayed a much stronger phenotype than 4-week Ang,
including systolic heart failure in mice by 14 to 16 weeks
of age (17). The SS-31 for 4 weeks partially rescued the
heart failure phenotype in mice overexpressing Gq,
including a significant amelioration of systolic dysfunc-
tion, cardiac hypertrophy, and myocardial performance
(Figs. 7A, 7D, and 7E).
Central to the scheme hypothesized in Figure 8 is the
amplification of mitochondrial ROS, which can occur by
multiple mechanisms. Ang is a key mediator of hyperten-
sion that binds to ATR1, a Gq coupled-receptor, then
tion of p38 MAPK, and Apoptosis
nsin II (Ang) or by Gq overexpression, and this was significantly attenuated by
leaved caspase 3 message, and this was significantly attenuated by SS-31. (C)
ed after Ang but was substantially lower in SS-31–treated hearts (upper panel).
de-3-phosphate dehydrogenase.ctiva
angiote
es in c
increas
aldehyactivates NADPH oxidase through a protein kinase
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NADPH oxidase has been shown to mediate Ang effects,
the NOX4 isoform has recently been reported to increase in
response to various hypertrophic stimuli (6) and is localized
in mitochondria (7), and activation of this isoform increases
mitochondrial ROS (6). Although our hypothesis indicates
that ROS produced directly from NOX4 and/or indirectly
by NOX2 isoform is amplified within mitochondria, the
relative contribution of these isoforms in elevating ROS in
mitochondria is not yet clear, and it is possible that
NOX-independent mechanism(s) might also contribute to
the Ang and Gq phenotypes.
Because escape of electrons from the mitochondrial
electron transport complexes is a principal source of cellular
ROS, oxidative damage to these complexes has been pro-
posed to lead to a vicious cycle (27). Another potential
mechanisms of Ang-induced mitochondrial ROS could be
the previously reported ROS-induced ROS release from
mitochondria, which might be mediated by activation of the
inner mitochondrial anion channel (inhibited by
4-chlorodiazepam) (28), or the mitochondrial permeability
transition pore (inhibited by cyclosporine) (29), or mito-
chondrial KATP channels (activated by diazoxide) (4). The
involvement of ROS-induced ROS release from mitochon-
dria should be considered as a primary mechanism of
Figure 7 SS-31 Ameliorated Cardiac Hypertrophy and Failure in
Echocardiography of Gq mice, 16 weeks of age. (A) SS-31 (3 mg/kg/day) for 4 w
tion, as indicated by fractional shortening (FS) in Gq mice. (B, C) Chamber enlar
statistical trend, p  0.08 and 0.06, respectively. (D) Worsening of myocardial pe
increase in normalized heart weight in Gq mice was substantially protected by SS
weight by SS-31 (p  0.09), n  3 to 6. LVEDD  left ventricular end diastolic diaAng-induced ROS signaling (30), as confirmed by ob-servations that Ang-induced mitochondrial-ROS was
reduced by simultaneous treatment with diazoxide,
4-chlorodiazepam, or cyclosporine A (Online Fig. 1). This
places mitochondria in a central position for signal ampli-
fication and, conversely, for therapeutic targeting. Although
most antihypertensive medications act upstream at the
receptor level (beta-blockers, calcium channel blockers,
angiotensin receptor blockers) or even at remote sites of
action (diuretics, angiotensin-converting enzyme inhibitor),
antioxidants provide an alternate intervention strategy in
cardiac hypertrophy and failure. Several antioxidant studies
have demonstrated some protective effect in cardiovascular
diseases. For instance, Euk-8, a superoxide dismutase and
catalase mimetic, ameliorated heart failure in ROS-sensitive
mouse models subjected to pressure overload (31). Zhou et
al. (32) reported that overexpression of metallothionein
suppressed oxidative and nitrosative stress, apoptosis, and
pathological remodeling in response to a short-term sub-
pressor dose of Ang. Our study, however, points to the
rationale of targeting antioxidants to mitochondria. The mi-
tochondrial antioxidant MitoQ has been shown to reduce BP
in the spontaneous hypertensive rat, concomitant with im-
provement of endothelial function and reduction of heart
weight; however, the mechanism of cardioprotection was
unclear (33). Our study found no effect of SS-31 on BP but
Overexpressing Mice
(from age 12 to 16 weeks) significantly ameliorated the decline in systolic func-
t and diastolic dysfunction in Gq mice were slightly attenuated by SS-31 with a
nce index (MPI) in Gq mice was significantly ameliorated by SS-31. (E) An
hereas there was a trend toward protection from increased normalized lung
; WT  wild-type.Gq
eeks
gemen
rforma
-31, w
metershowed evidence of direct cardioprotective mechanisms involv-
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of apoptosis and fibrosis, and attenuation of p38 MAP kinase
activation.
Hypertension is a highly prevalent disease that imposes a
major risk for the development of atherosclerosis, cardio-
myopathy, stroke, sudden cardiac death, and heart failure.
Hypertension-induced heart failure might be manifested as
systolic heart failure or heart failure with preserved ejection
fraction (HFpEF); the latter accounts for nearly one-half of
the patients with heart failure, and the prognosis of HFpEF
is only marginally better than that of systolic heart failure
(34). Although antihypertensive treatment reduces mortal-
ity and improves quality of life in patients with established
systolic heart failure (35), there is no convincing evidence
for any effective treatment of HFpEF. These underscore the
urgent need to develop new prevention and treatment
strategies for hypertensive cardiovascular diseases. Although
clinical trials applying antioxidants to disease prevention in
general and cardioprotection in particular (36) have been
disappointing, these studies have generally used nontargeted
cellular antioxidants. Our study demonstrates that a
mitochondrial-targeted antioxidant drug is beneficial in
preventing hypertension-induced target organ damage and
Figure 8
Diagrammatic Illustration of the
Proposed Mechanisms of SS-31 Protection
in Ang- and Gq-Induced Cardiomyopathy
Ang and Gq activate NOX isoforms that might directly (NOX4) or indirectly
(NOX2) elevate mitochondrial reactive oxygen species (ROS). Amplification by
ROS-induced ROS mechanisms might facilitate ROS-mediated activation of sig-
naling in hypertrophy and failure. Abbreviations as in Figures 3 and 6.provides a strong rationale for investigating its clinicalapplication for the treatment or prevention of hypertensive
cardiovascular diseases.
Reprint requests and correspondence: Dr. Peter S. Rabinovitch,
Department of Pathology, University of Washington, 1959 Pacific
Avenue Northeast, HSB-K081, Seattle, Washington 98195.
E-mail: petersr@u.washington.edu.
REFERENCES
1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-
pressure-related disease, 2001. Lancet 2008;371:1513–8.
2. Gardin JM, Lauer MS. Left ventricular hypertrophy: the next treat-
able, silent killer? JAMA 2004;292:2396–8.
3. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II
infusion on the expression and function of NAD(P)H oxidase and
components of nitric oxide/cGMP signaling. Circ Res 2002;90:
E58 – 65.
4. Kimura S, Zhang GX, Nishiyama A, et al. Mitochondria-derived
reactive oxygen species and vascular MAP kinases: comparison of
angiotensin II and diazoxide. Hypertension 2005;45:438–44.
5. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of
angiotensin II-mediated mitochondrial dysfunction: linking mito-
chondrial oxidative damage and vascular endothelial dysfunction. Circ
Res 2008;102:488–96.
6. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation
of Nox4 by hypertrophic stimuli promotes apoptosis and mitochon-
drial dysfunction in cardiac myocytes. Circ Res 2010;106:1253– 64.
7. Block K, Gorin Y, Abboud HE. Subcellular localization of Nox4 and
regulation in diabetes. Proc Natl Acad Sci U S A 2009;106:14385–90.
8. Schriner SE, Linford NJ, Martin GM, et al. Extension of murine life
span by overexpression of catalase targeted to mitochondria. Science
2005;308:1909–11.
9. Dai DF, Santana LF, Vermulst M, et al. Overexpression of catalase
targeted to mitochondria attenuates murine cardiac aging. Circulation
2009;119:2789–97.
10. Szeto HH. Mitochondria-targeted cytoprotective peptides for
ischemia-reperfusion injury. Antioxid Redox Signal 2008;10:601–19.
11. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants
targeted to inner mitochondrial membrane inhibit mitochondrial
swelling, oxidative cell death, and reperfusion injury. J Biol Chem
2004;279:34682–90.
12. Whiteman M, Spencer JP, Szeto HH, Armstrong JS. Do mitochon-
driotropic antioxidants prevent chlorinative stress-induced mitochon-
drial and cellular injury? Antioxid Redox Signal 2008;10:641–50.
13. Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-targeted
peptide prevents mitochondrial depolarization and apoptosis induced
by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol
2005;70:1796–806.
14. Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. A novel
cell-permeable antioxidant peptide, SS31, attenuates ischemic brain
injury by down-regulating CD36. J Biol Chem 2007;282:4634–42.
15. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. Mitochon-
dria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine neurotoxicity. Antioxid Redox Signal 2009;11:2095–104.
16. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2
emission and cellular redox state link excess fat intake to insulin
resistance in both rodents and humans. J Clin Invest 2009;119:
573– 81.
17. D’Angelo DD, Sakata Y, Lorenz JN, et al. Transgenic Galphaq
overexpression induces cardiac contractile failure in mice. Proc Natl
Acad Sci U S A 1997;94:8121–6.
18. Byrne JA, Grieve DJ, Bendall JK, et al. Contrasting roles of NADPH
oxidase isoforms in pressure-overload versus angiotensin II-induced
cardiac hypertrophy. Circ Res 2003;93:802–5.
19. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling
mitochondrial biogenesis and respiration through the thermogenic
coactivator PGC-1. Cell 1999;98:115–24.
20. Izumiya Y, Kim S, Izumi Y, et al. Apoptosis signal-regulating kinase
1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy
and remodeling. Circ Res 2003;93:874–83.
82 Dai et al. JACC Vol. 58, No. 1, 2011
Mitochondrial Antioxidant and Cardiomyopathy June 28, 2011:73–8221. Clerk A, Fuller SJ, Michael A, Sugden PH. Stimulation of “stress-
regulated” mitogen-activated protein kinases (stress-activated protein
kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein
kinases) in perfused rat hearts by oxidative and other stresses. J Biol
Chem 1998;273:7228–34.
22. Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of
nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol
Chem 2001;276:5197–203.
23. Liu Q, Wilkins BJ, Lee YJ, Ichijo H, Molkentin JD. Direct interaction
and reciprocal regulation between ASK1 and calcineurin-NFAT control
cardiomyocyte death and growth. Mol Cell Biol 2006;26:3785–97.
24. St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen
species and neurodegeneration by the PGC-1 transcriptional coacti-
vators. Cell 2006;127:397–408.
25. Li M, Georgakopoulos D, Lu G, et al. p38 MAP kinase mediates
inflammatory cytokine induction in cardiomyocytes and extracellu-
lar matrix remodeling in heart. Circulation 2005;111:2494 –502.
26. See F, Thomas W, Way K, et al. p38 mitogen-activated protein kinase
inhibition improves cardiac function and attenuates left ventricular
remodeling following myocardial infarction in the rat. J Am Coll
Cardiol 2004;44:1679–89.
27. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging.
Cell 2005;120:483–95.
28. Aon MA, Cortassa S, Akar FG, Brown DA, Zhou L, O’Rourke B.
From mitochondrial dynamics to arrhythmias. Int J Biochem Cell Biol
2009;41:1940–8.
29. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive
oxygen species (ROS)-induced ROS release: a new phenomenon
accompanying induction of the mitochondrial permeability transition
in cardiac myocytes. J Exp Med 2000;192:1001–14.30. Brown DA, Aon MA, Akar FG, Liu T, Sorarrain N, O’Rourke B.
Effects of 4=-chlorodiazepam on cellular excitation-contraction cou-
pling and ischaemia-reperfusion injury in rabbit heart. Cardiovasc Res
2008;79:141–9.
31. van Empel VP, Bertrand AT, van Oort RJ, et al. EUK-8, a superoxide
dismutase and catalase mimetic, reduces cardiac oxidative stress and
ameliorates pressure overload-induced heart failure in the harlequin
mouse mutant. J Am Coll Cardiol 2006;48:824–32.
32. Zhou G, Li X, Hein DW, et al. Metallothionein suppresses angio-
tensin II-induced nicotinamide adenine dinucleotide phosphate oxi-
dase activation, nitrosative stress, apoptosis, and pathological remod-
eling in the diabetic heart. J Am Coll Cardiol 2008;52:655–66.
33. Graham D, Huynh NN, Hamilton CA, et al. Mitochondria-targeted
antioxidant MitoQ10 improves endothelial function and attenuates
cardiac hypertrophy. Hypertension 2009;54:322–8.
34. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield
MM. Trends in prevalence and outcome of heart failure with preserved
ejection fraction. N Engl J Med 2006;355:251–9.
35. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease
continuum validated: clinical evidence of improved patient outcomes:
part I: pathophysiology and clinical trial evidence (risk factors through
stable coronary artery disease). Circulation 2006;114:2850–70.
36. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J
Cardiol 2008;101:14D–9D.
Key Words: cardiomyopathy y hypertension y mitochondria.
APPENDIX
For supplementary figures and Methods,
please see the online version of this article.
